Search - tctmd.com

Displaying 161 - 180 of 555

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

Shelley Wood

September 30, 2017

Top Stories in Cardiology, September 2017

Podcast Heart Sounds

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Daily News

No More Absorb BVS: Abbott Puts a Stop to Sales

Caitlin E. Cox

September 08, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

Caitlin E. Cox

August 31, 2017

News Daily News

Boston Scientific Scraps Biodegradable Scaffold Program

Michael O'Riordan

August 01, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2017

Shelley Wood

July 31, 2017

News Daily News

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

Shelley Wood

July 21, 2017

News Daily News

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

Yael L. Maxwell

June 29, 2017

Presentation TVT 2017

Fully Absorbable Patch-Based Large Hole Vascular Closure Device - EU Multi-center Clinical Experience

Presenter: Juan F. Granada, Martin B. Leon, Gregg W. Stone, Michael Laule, MD

June 14, 2017

Podcast

Episode 14: ABSORB II, the Future of BRS, and Post-TAVR Thrombosis

June 07, 2017

News Conference News EuroPCR 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Shelley Wood

June 02, 2017

News Features EuroPCR 2017

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

Yael L. Maxwell

June 01, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Conference News EuroPCR 2017

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

Michael O'Riordan

May 19, 2017

Presentation EuroPCR 2017

ABSORB Japan Results: 3-year Clinical and Angiographic Results

Presenter: Ken Kozuma

May 17, 2017

Presentation EuroPCR 2017

Randomized Comparison of Everolimus-eluting Bioresorbable Vascular Scaffolds vs. Everolimus-eluting Metallic Stents in Patients with Coronary Artery Disease: 3-year Clinical Outcomes from ABSORB China

Presenter: Runlin Gao

May 17, 2017

Presentation SCAI 2017

Absorb Scaffolds Will Be Used In Most Patients One Day

Presenter: Cindy L Grines

May 17, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

Advertisement

TCTMD’s Top 10 Most Popular Stories for September 2017

Top Stories in Cardiology, September 2017

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

No More Absorb BVS: Abbott Puts a Stop to Sales

TCTMD’s Top 10 Most Popular Stories for August 2017

Boston Scientific Scraps Biodegradable Scaffold Program

TCTMD’s Top 10 Most Popular Stories for July 2017

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

Fully Absorbable Patch-Based Large Hole Vascular Closure Device - EU Multi-center Clinical Experience

Episode 14: ABSORB II, the Future of BRS, and Post-TAVR Thrombosis

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

TCTMD’s Top 10 Most Popular Stories for May 2017

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

ABSORB Japan Results: 3-year Clinical and Angiographic Results

Randomized Comparison of Everolimus-eluting Bioresorbable Vascular Scaffolds vs. Everolimus-eluting Metallic Stents in Patients with Coronary Artery Disease: 3-year Clinical Outcomes from ABSORB China

Absorb Scaffolds Will Be Used In Most Patients One Day

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content